WP1. Drug Discovery
Work package leader: University of Valladolid (UVA)
The objective of WP1 is to synthesize, isolate and evaluate potential lead compounds in vitro. The most promising ones will be selected for the in vivo proof of concept study in WP2.
The following Early Stage Researchers (ESRs) will conduct their research in this work-package:
WP2. Preclinical drug development
Work package leader: University of Eastern Finland (UEF)
In WP2, compounds that have passed the selection criteria of WP1 will be upscaled and further evaluated in formulation and pharmacokinetics (PK) studies and in vivo proof of concept studies.
The following Early Stage Researchers (ESRs) will conduct their research in this work-package:
WP3. Development of clinical diagnostic tools
Work package leader: Sorbonne Université (SU)
This WP3 aims to develop new optical and molecular biomarkers for pre-clinical and clinical evaluation in dry eye disease.
The following Early Stage Researchers (ESRs) will conduct their research in this work-package: